BSG and hepatocellular carcinoma: The anti-CD147 antibody was bound to dextran nanoparticles in the trial for lung cancer [76], conjugated to liposomes for hepatoma [77], or to phosphoester polymeric nanoparticles for hepatocellular carcinoma [78].